Cargando…

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog(®)), and European Union-sourced insulin aspart (NovoRapid(®)). Materials and Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapitza, Christoph, Nosek, Leszek, Schmider, Wolfgang, Teichert, Lenore, Nowotny, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104901/
https://www.ncbi.nlm.nih.gov/pubmed/31825248
http://dx.doi.org/10.1089/dia.2019.0351
_version_ 1783512306286592000
author Kapitza, Christoph
Nosek, Leszek
Schmider, Wolfgang
Teichert, Lenore
Nowotny, Irene
author_facet Kapitza, Christoph
Nosek, Leszek
Schmider, Wolfgang
Teichert, Lenore
Nowotny, Irene
author_sort Kapitza, Christoph
collection PubMed
description Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog(®)), and European Union-sourced insulin aspart (NovoRapid(®)). Materials and Methods: This was a single-center, randomized, double-blind, 3-treatment, 3-period, single-dose, crossover euglycemic study (NCT03202875) in 30 adult male subjects with type 1 diabetes (T1D). Subjects received 0.3 U/kg of each treatment under fasted conditions and underwent a 12-h euglycemic clamp technique to assess pharmacokinetic and pharmacodynamic activity for up to 12 h. Primary endpoints were area under the plasma insulin concentration–time curve from time zero to the last quantifiable concentration (INS-AUC(last)), and extrapolated to infinity (INS-AUC(inf)), maximum plasma insulin concentration (INS-C(max)), and the area under the body weight-standardized glucose infusion rate (GIR)–time curve from 0 to 12 hours (GIR-AUC(0–12h)) among the three treatments. GIR(max) was the main secondary endpoint. Results: Of the 30 subjects randomized, 29 completed all 3 treatment periods. Pharmacokinetic and pharmacodynamic profiles were similar in all groups. The extent of exposure (INS-C(max), INS-AUC(last), and INS-AUC(inf)) and glucodynamic activity (GIR-AUC(0–12h), GIR(max)) was similar among the three treatments. The corresponding 90% confidence intervals for pairwise treatment ratios were completely contained within the limits of 80%–125%. SAR341402 was well tolerated. Conclusions: The present study demonstrated similar pharmacokinetic exposure profiles and glucodynamic potency among SAR341402, NovoLog, and NovoRapid in subjects with T1D, supporting further clinical evaluation of SAR341402 as a biosimilar/follow-on product.
format Online
Article
Text
id pubmed-7104901
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-71049012020-03-31 Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes Kapitza, Christoph Nosek, Leszek Schmider, Wolfgang Teichert, Lenore Nowotny, Irene Diabetes Technol Ther Original Articles Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog(®)), and European Union-sourced insulin aspart (NovoRapid(®)). Materials and Methods: This was a single-center, randomized, double-blind, 3-treatment, 3-period, single-dose, crossover euglycemic study (NCT03202875) in 30 adult male subjects with type 1 diabetes (T1D). Subjects received 0.3 U/kg of each treatment under fasted conditions and underwent a 12-h euglycemic clamp technique to assess pharmacokinetic and pharmacodynamic activity for up to 12 h. Primary endpoints were area under the plasma insulin concentration–time curve from time zero to the last quantifiable concentration (INS-AUC(last)), and extrapolated to infinity (INS-AUC(inf)), maximum plasma insulin concentration (INS-C(max)), and the area under the body weight-standardized glucose infusion rate (GIR)–time curve from 0 to 12 hours (GIR-AUC(0–12h)) among the three treatments. GIR(max) was the main secondary endpoint. Results: Of the 30 subjects randomized, 29 completed all 3 treatment periods. Pharmacokinetic and pharmacodynamic profiles were similar in all groups. The extent of exposure (INS-C(max), INS-AUC(last), and INS-AUC(inf)) and glucodynamic activity (GIR-AUC(0–12h), GIR(max)) was similar among the three treatments. The corresponding 90% confidence intervals for pairwise treatment ratios were completely contained within the limits of 80%–125%. SAR341402 was well tolerated. Conclusions: The present study demonstrated similar pharmacokinetic exposure profiles and glucodynamic potency among SAR341402, NovoLog, and NovoRapid in subjects with T1D, supporting further clinical evaluation of SAR341402 as a biosimilar/follow-on product. Mary Ann Liebert, Inc., publishers 2020-04-01 2020-03-24 /pmc/articles/PMC7104901/ /pubmed/31825248 http://dx.doi.org/10.1089/dia.2019.0351 Text en © Christoph Kapitza, et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Articles
Kapitza, Christoph
Nosek, Leszek
Schmider, Wolfgang
Teichert, Lenore
Nowotny, Irene
Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
title Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
title_full Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
title_fullStr Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
title_full_unstemmed Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
title_short Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
title_sort single-dose euglycemic clamp study demonstrating pharmacokinetic and pharmacodynamic similarity between sar341402 insulin aspart and us- and eu-approved versions of insulin aspart in subjects with type 1 diabetes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104901/
https://www.ncbi.nlm.nih.gov/pubmed/31825248
http://dx.doi.org/10.1089/dia.2019.0351
work_keys_str_mv AT kapitzachristoph singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes
AT nosekleszek singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes
AT schmiderwolfgang singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes
AT teichertlenore singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes
AT nowotnyirene singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes